These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1053883)

  • 1. Treatment of hemophilic patients with factor VIII inhibitor.
    Abildgaard CF; Britton M
    Ann N Y Acad Sci; 1975 Jan; 240():400-4. PubMed ID: 1053883
    [No Abstract]   [Full Text] [Related]  

  • 2. [Elimination of inhibitors in children with hemophilia A].
    Weissbach G; Domula M; Lenk H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):817-25. PubMed ID: 6083958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance.
    Kobrinsky NL; Sjolander DE; Moser DK; Stegman DA
    Am J Hematol; 2004 Jun; 76(2):180-4. PubMed ID: 15164387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII.
    Montoro JB; Rodríguez S; Altisent C; Tusell JM
    Lancet; 1991 May; 337(8751):1222. PubMed ID: 1673757
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of anti-factor VIII antibodies.
    Blatt PM; White GC; McMillan CW; Roberts HR
    Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: Hemophilia: cyclophosphamide and factor VIII concentrate.
    Stein RS
    Ann Intern Med; 1974 Nov; 81(5):706-7. PubMed ID: 4419955
    [No Abstract]   [Full Text] [Related]  

  • 7. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.
    Nilsson IM; Hedner U; Holmberg L
    Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094
    [No Abstract]   [Full Text] [Related]  

  • 8. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M; Anders O; Schmidt M; Roewer J
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia.
    Hruby MA; Schulman I
    Blood; 1973 Dec; 42(6):919-23. PubMed ID: 4759918
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
    Nilsson IM; Berntorp E; Zettervall O
    N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary trial of cyclophosphamide in the management of hemophiliacs with factor VIII inhibitors.
    Ruggeri ZM; Mannucci PM; Allain JP; Frommel D
    Ann N Y Acad Sci; 1975 Jan; 240():412-8. PubMed ID: 1053886
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor VIII inhibitors in hemophilia.
    Mariani G
    Bilt Hematol Transfuz; 1979; 7(1):3-41. PubMed ID: 121880
    [No Abstract]   [Full Text] [Related]  

  • 14. Panel discussion on the treatment of patients with factor VIII inhibitors.
    Lusher JM; Eyster ME; Hilgartner MW; Kasper CK; Mannucci PM; Nilsson IM; Penner JA; Roberts HR
    Prog Clin Biol Res; 1984; 150():323-35. PubMed ID: 6431437
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group.
    Nuss R; Jacobson L; Hathaway WE; Manco-Johnson M
    Thromb Haemost; 1999 Nov; 82(5):1559-60. PubMed ID: 10595659
    [No Abstract]   [Full Text] [Related]  

  • 16. [Exchange transfusion in the treatment of the hemophilic child with factor VIII inhibitors].
    Benítez-Aranda H; Farfán Canto JM; Esparza-Flores MA; Bernaldez-Ríos R; Alvarez-Amaya C
    Bol Med Hosp Infant Mex; 1985 Nov; 42(11):687-91. PubMed ID: 3936511
    [No Abstract]   [Full Text] [Related]  

  • 17. Transient inhibitor to monoclonal antibody-purified factor VIII concentrate.
    Votaw ML; Miller S
    Am J Hematol; 1992 Dec; 41(4):297. PubMed ID: 1288295
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
    Sultan Y; Brouet JC
    Nouv Presse Med; 1975 Oct; 4(36):2571-4. PubMed ID: 1081682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and trends in the treatment of hemophilic patients with inhibitors.
    Bloom AL
    Prog Clin Biol Res; 1981; 72():123-38. PubMed ID: 6801682
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.